STAAR Surgical Celebrates 30th Anniversary of Implantable Collamer® Lens (ICL)
2023年10月17日 - 8:00PM
ビジネスワイヤ(英語)
ICL Corrects/Reduces Refractive Error for
Glasses and Contact Lens Wearers
99.4% of Patients Surveyed Would Have ICL
Procedure Again1
STAAR Surgical Company (NASDAQ: STAA), a leading developer,
manufacturer and marketer of implantable lenses for the eye, is
celebrating the 30th anniversary of its proprietary Implantable
Collamer® Lens (ICL). The first ICLs were implanted by a group of
surgeons in October 1993, including Roberto Zaldivar, MD, Founder
of the Zaldivar Institute. The early ICLs have evolved into the
current generation of ICLs with a central port – the EVO ICL™
family of lenses.
“We celebrate the 30th anniversary of our ICL technology with
surgeons and patients,” said Tom Frinzi, President and CEO of STAAR
Surgical. “The collaboration between ophthalmic surgeons and
industry is important and unique for advancing innovative
technologies like ICL. We are proud of our association with Dr.
Zaldivar and the many other clinicians that work with STAAR to
positively impact the millions of patients who will benefit from
our lenses.”
Myopia (nearsightedness), the most common refractive visual
error, is a global epidemic that is expected to impact over half
the world’s population by 2050.2 EVO ICLs offer a lens-based
alternative for the correction/reduction of refractive error in
people who currently use glasses and/or contact lenses for vision
correction.
The EVO procedure involves implanting (or adding) a proprietary
and biocompatible EVO ICL into the eye between the iris (colored
part of the eye) and the natural lens to correct/reduce
nearsightedness with and without astigmatism. The entire EVO ICL
procedure typically takes about 20–30 minutes and most patients
experience improved vision right after the procedure. The EVO ICL
can permanently correct vision without removing corneal tissue and,
if desired, is removable by a doctor for added peace of mind. EVO
ICL gives the patient flexibility for the future, while also
helping to eliminate dependency on glasses and contact lenses
now.
STAAR began selling the ICL in 1996. The ICL with the central
port (EVO ICL) was first approved for commercial use in CE Mark
countries in 2011 and in the United States in 2022.
1 Packer M. The Implantable Collamer Lens with a central port:
review of the literature. Clinical Ophthalmology 2018:
12:2427–2438. 2 Holden BA, Fricke TR, Wilson DA, et al. Global
Prevalence of Myopia and High Myopia and Temporal Trends from 2000
through 2050. Ophthalmology. 2016.
About STAAR Surgical
STAAR, which has been dedicated solely to ophthalmic surgery for
over 40 years, designs, develops, manufactures and markets
implantable lenses for the eye. These lenses are intended to
provide visual freedom for patients, lessening or eliminating the
reliance on glasses or contact lenses. All of these lenses are
foldable, which permits the surgeon to insert them through a small
incision. STAAR’s lens used in refractive surgery is called an
Implantable Collamer® Lens or “ICL,” which includes the EVO ICL™
product line. More than 2,500,000 ICLs have been sold to date and
STAAR markets these lenses in over 75 countries. To learn more
about the ICL go to: EVOICL.com. Headquartered in Lake Forest, CA,
the company operates manufacturing and packaging facilities in
Aliso Viejo, CA, Monrovia, CA, and Nidau, Switzerland. For more
information, please visit the Company’s website at
www.staar.com
Important Safety Information for EVO ICL
The EVO Visian ICL lens is intended to correct/reduce
nearsightedness between -3.0 D up to -20.0 D and treat astigmatism
from 1.0 D to 4.0 D. If you have nearsightedness within these
ranges, EVO Visian ICL surgery may improve your distance vision
without eyeglasses or contact lenses. Because the EVO Visian ICL
corrects for distance vision, it does not eliminate the need for
reading glasses, you may require them at some point, even if you
have never worn them before. Since implantation of the EVO Visian
ICL is a surgical procedure, before considering EVO Visian ICL
surgery you should have a complete eye examination and talk with
your eye care professional about EVO Visian ICL surgery, especially
the potential benefits, risks, and complications. You should
discuss the time needed for healing after surgery. Complications,
although rare, may include need for additional surgical procedures,
inflammation, loss of cells from the back surface of the cornea,
increase in eye pressure, and cataracts. You should NOT have EVO
Visian ICL surgery if your doctor determines that 1) the shape of
your eye is not appropriate, 2) you do not meet the minimum
endothelial cell density for your age at the time of implantation,
3) you have moderate to severe glaucoma, 4) your vision is not
stable; or 5) if you are pregnant or nursing. For additional
information with potential benefits, risks and complications please
visit DiscoverICL.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231017562658/en/
Investors & Media Brian Moore Vice President,
Investor, Media Relations and Corporate Development (626) 303-7902,
Ext. 3023 bmoore@staar.com
STAAR Surgical (NASDAQ:STAA)
過去 株価チャート
から 4 2024 まで 5 2024
STAAR Surgical (NASDAQ:STAA)
過去 株価チャート
から 5 2023 まで 5 2024